Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])

The summary for the Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])
	CFDA Number:	93.855
	CFDA Description:	Allergy, Immunology and Transplantation Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-09-093
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Feb 09, 2009
	Creation Date:	Feb 09, 2009
	Original Closing Date for Applications:	Jan 07, 2012
	Current Closing Date for Applications:	Jan 07, 2012
	Archive Date:	Feb 07, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Information not provided
Grant Description: Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to continue and expand non-clinical and pre-clinical efforts for product development of radiological/nuclear medical countermeasures effective for 1) the mitigation or treatment of acute radiation syndromes and long-term or delayed effects, 2) the treatment of internal radionuclide contamination with decorporation agents, and 3) the determination of individual radiation exposure levels with radiation biodosimetry products for potential use during a radiological emergency.Applications proposing candidate product(s) that mitigate and/or treat acute and long-term radiation injury due to lethal exposures or facilitate the elimination of internal radionuclide contamination; or that propose means of accurately estimating radiation dose received (biodosimetry) are solicited.Applications should support product development efforts leading to the submission of Investigational New Drug Applications (IND) or Investigational Device Exemptions (IDE) to the U.S. Food and Drug Administration (FDA) to facilitate eventual licensure and potential inclusion in the Strategic National Stockpile (SNS). Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I and Phase II applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-09-093.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Innovation for HIV Vaccine Discovery (R01); • NIAID Clinical Trial Implementation Cooperative Agreement (U01); • Therapeutics for Neurotropic Biodefense Toxins and Pathogens (R21/R33); • Strategies for the Protection of Pregnant Women and Infants Against Infectious Diseases (R01); • Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Inj...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers; • Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01); • Asthma and Allergic Diseases Cooperative Research Centers (U19)